SCHEMBL4617952

SCHEMBL4617952

O=S(=O)(O)C=Cc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.52
AHR P35869 1/20 0.50
NFE2L2 Q16236 4/20 0.49
PPARG P37231 1/20 0.47
ALOX5 P09917 1/20 0.46
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
MAOB P27338 2/20 0.45
HSD17B10 Q99714 1/20 0.44
PTGES2 Q9H7Z7 1/20 0.44
FBP1 P09467 1/20 0.44
HDAC2 Q92769 2/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4617948 1.00 CYP1A2 (0.52) CYP1A2AHRNFE2L2PPARGALOX5
SCHEMBL28760348 0.82 CA12 (0.40) NFE2L2PPARGPTGES2HDAC2HDAC3
SCHEMBL4618879 0.81 SMN1; SMN2 (0.44) CYP1A2MAOBHDAC1HDAC8CXCL12
SCHEMBL950722 0.80 HSD17B10 (0.52) CYP1A2AHRNFE2L2PPARGALOX5
SCHEMBL950718 0.80 HSD17B10 (0.52) CYP1A2AHRNFE2L2PPARGALOX5
SCHEMBL2298614 0.80 APP (0.52) CYP1A2NFE2L2PPARGALOX5PTGS1
SCHEMBL2298611 0.80 APP (0.52) CYP1A2NFE2L2PPARGALOX5PTGS1
SCHEMBL2130152 0.78 NFE2L2 (0.53) CYP1A2AHRNFE2L2PPARGALOX5
SCHEMBL2173890 0.78 LMNA (0.53) NFE2L2PPARGALOX5PTGS1PTGS2
SCHEMBL29496 0.78 TDP1 (0.57) CYP1A2NFE2L2PPARGMAOBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1684744-A4 PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2008-12-17 EP claimed
US-7169795-B2 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL MYERS SQUIBB COMPANY (US) 2007-01-30 US claimed
EP-1684744-A2 PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2006-08-02 EP claimed
US-20050119266-A1 Pyrrolidine and piperidine derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-06-02 US claimed
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-05-05 US claimed
WO-2005032472-A2 PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 WO claimed
US-4263201-A ORGANIC ACID METAL SALT, HALOGEN COMPOUND GENERAL ELECTRIC COMPANY (US) 1981-04-21 US claimed
US-12185579-B2 Organic light emitting diode and manufacturing method thereof, and display panel WUHAN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2024-12-31 US disclosed
US-20240023370-A1 ORGANIC LIGHT EMITTING DIODE AND MANUFACTURING METHOD THEREOF, AND DISPLAY PANEL WUHAN CHINA STAR OPTOELECTRONICS TECHNOLOGY CO., LTD. (CN) 2024-01-18 US disclosed
WO-2023272815-A1 ORGANIC LIGHT-EMITTING DIODE, PREPARATION METHOD THEREFOR, AND DISPLAY PANEL 武汉华星光电技术有限公司 2023-01-05 WO disclosed
CN-113471374-A Organic light emitting diode, preparation method thereof and display panel 武汉华星光电技术有限公司 2021-10-01 CN disclosed
EP-1684744-A4 PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2008-12-17 EP disclosed
CN-101268042-A Styryl sulfonamides, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-09-17 CN disclosed
EP-1667635-A2 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2006-06-14 EP disclosed
WO-2005048922-A2 SULFONYLAMINOVALEROLACTAMS AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-02 WO disclosed
US-20050119266-A1 Pyrrolidine and piperidine derivatives as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-06-02 US disclosed
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2005-05-05 US disclosed
WO-2005032472-A2 PYRROLIDINE AND PIPERIDINE DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-04-14 WO disclosed
US-4075164-A AROMATIC CARBONATE POLYMER GENERAL ELECTRIC COMPANY (US) 1978-02-21 US disclosed
US-3940366-A AROMATIC METAL SULFONATE GENERAL ELECTRIC COMPANY (US) 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119266-A1 Pyrrolidine and piperidine derivatives as factor Xa inhibitors PEPD, SERPINE1, PRSS1 CYP1A2 3037/4885AHR 4474/4885NFE2L2 4151/4885
US-20050096309-A1 Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors TFPI, F12, F5 CYP1A2 2107/4885AHR 3640/4885NFE2L2 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.